Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12163682 | 0.84 | POLB (0.55) | KDM4EALDH1A1HPGDGAAPDE4B | |
| SCHEMBL5025952 | 0.82 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDL3MBTL1PDE4B | |
| SCHEMBL17595583 | 0.82 | PDE4B (0.46) | KDM4EALDH1A1HPGDGAAPDE4B | |
| SCHEMBL12704717 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1HPGDL3MBTL1GAA | |
| SCHEMBL5024807 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1HPGDGAAPDE4B | |
| SCHEMBL5022215 | 0.76 | SLC9A1 (0.42) | KDM4EPDE4BMAPTMAPK1HSD17B10 | |
| SCHEMBL3538865 | 0.76 | TARBP2 (0.53) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL12163678 | 0.75 | PDE4B (0.54) | KDM4EALDH1A1PDE4BMAPTMEN1 | |
| SCHEMBL5783310 | 0.75 | KDM4E (0.57) | KDM4EALDH1A1HPGDPDE4BMAPT | |
| SCHEMBL2329392 | 0.74 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100577660-C | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists used for the treatment of diabetes | HOFFMANN LA ROCHE | 2010-01-06 | — | — | CN | disclosed |
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1539746-B1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | disclosed |
| CN-1681808-A | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | KDM4E 2287/4885ALDH1A1 54/4885HPGD 2382/4885 |
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | KDM4E 4377/4885ALDH1A1 2575/4885HPGD 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.